Photo

Photo detail

Photo courtesy of Merck.
Merck will tap Janux’s Tumor Activated T Cell Engager (TRACTr) tech to engineer new drug candidates against two cancer targets selected by Merck.

Stories this photo appears in:

Janux Partners With Merck

BIOTECH: Deal Worth More Than $1 Billion

Tease photo